RxSpark Blog

At RxSpark we believe prescription drugs and medication should be accessible and affordable for all Americans. In addition to the savings, discounts, and convenience that RxSpark provides, the RxSpark Blog is here to bring you information, news, current events, and important upates on topics that affect healthcare and prescription drugs. Be sure to check back frequently for updates, and if you find any information that is particularly helpful please don't hesitate to share!



5 Top Tips for Safe Medication Management

The number of prescriptions filled in the U.S. has risen from 2.4 billion 1997 to 4.4 billion in 2016, according to figures from Quintiles IMS. With a recent Consumer Reports survey showing more than half of Americans regularly take prescription medication, the need for organized and safe medication...

Read More

Vyxeos approval a 'welcome therapeutic advance for AML patients'

Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration (FDA). It is the first treatment approved for patients with certain types of high-risk acute myeloid leukemia (AML). The drug, developed by Jazz Pharmaceuticals, is a fixed combination of two chemotherapy...

Read More

FDA requests feedback on its guidances for generic drug development

The U.S. Food and Drug Administration (FDA) has released its latest guidelines for the development of generic drugs and has requested feedback and comments on its guidance. Recently, the FDA has taken steps to increase the number of generic drugs available in the U.S. and is on track to make a recor...

Read More

BASE10 Genetics: The next step in precision medicine and DNA testing

Pharmacists have always been on the frontline of healthcare, providing medication and guidance to millions of American patients, and functioning as the first port of call for many in search of treatment and clinical advice. BASE10 is the latest innovation in precision medicine, providing patients wi...

Read More

HCV treatment with 98% cure rate gets FDA nod

The U.S. Food and Drug Administration (FDA) approved the hepatitis C virus (HCV) treatment Mavyret (glecaprevir, pibrentasvir), granting biopharmaceutical firm AbbVie Breakthrough Therapy Designation and Priority Review for the treatment of GT1 HCV patients not cured with prior direct-acting antivir...

Read More